NCIt definition : A human monoclonal antibody directed against the immunosuppressive ligand programmed
cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential
immune checkpoint inhibitory and antineoplastic activities. Upon administration, danburstotug
specifically targets and binds to PD-L1, blocking its binding to and activation of
its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279).
This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the
cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing
tumor cells. In addition, anti-PD-L1 monoclonal antibody IMC-001 also induces antibody-dependent
cell-mediated cytotoxicity (ADCC). PD-L1 is overexpressed by many human cancer cell
types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in
immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily
(IgSF) expressed on activated T-cells, is a negative regulator of the immune system
that limits the expansion and survival of CD8-positive T-cells.;
UNII : F44C4N45HG;
CAS number : 2307144-65-4;
Molecule name : IMC-001; STI3031; IMC 001; STI 3031;
Semantic type(s)